{
    "clinical_study": {
        "@rank": "143068", 
        "arm_group": [
            {
                "arm_group_label": "CVD, Omega-3", 
                "arm_group_type": "Active Comparator", 
                "description": "patients with Cardiovascular disease who receive 4g/d omega-3"
            }, 
            {
                "arm_group_label": "CVD, Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients with cardiovascular disease who receive 4 cap of placebo/day"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is the comparison between the effects of supplementation with omega 3\n      or placebo for 8 weeks in serum level of IGF-1 and IGFBP-3 and gene expression of IGF-1 in\n      patients with cardiovascular disease."
        }, 
        "brief_title": "Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CVD patients 45- 65 years old, patients with \u2265 50% stenosis in at least one coronary\n             angiogram demonstrated, body mass index in the range 18.5- 35, avoidance of dietary\n             supplements, vitamins and herbal products at least 3 months before and throughout the\n             intervention, willingness to participation,\n\n        Exclusion Criteria:\n\n          -  people who have used omega 3 supplements in last 3 months, having chronic renal\n             disease , GI disease, hepatobiliary diseases, hematological disorders, hypo- or\n             hyperthyroidism, Smokers"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092584", 
            "org_study_id": "5144"
        }, 
        "intervention": [
            {
                "arm_group_label": "CVD, Omega-3", 
                "description": "4 cap 1 g Omega-3 per day for 2 months", 
                "intervention_name": "Omega-3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "n-3 fatty acids", 
                    "n-3 PUFA"
                ]
            }, 
            {
                "arm_group_label": "CVD, Placebo", 
                "description": "4 cap 1 g Placebo(paraffin) per day for 2 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "atherosclerotic", 
            "IGF-1", 
            "IGFBP-3"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Tehran University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Serum Total Cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 2 months"
            }, 
            {
                "measure": "Serum HDL-C", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum LDL-C", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum TG", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum Fasting Blood Sugar(FBS)", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum Insulin", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum hsCRP", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum Insulin Like Growth Factor-1(IGF-1)", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Serum IGF binding protein 3(IGFBP-3)", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Gene Expression of IGF-1", 
                "safety_issue": "No", 
                "time_frame": "Change frome baseline at 2 months"
            }, 
            {
                "measure": "Gene expression of IGFBP3", 
                "safety_issue": "No", 
                "time_frame": "change from baseline at 2 months"
            }
        ], 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}